Compound: PEXACERFONT
SMILES: O(c1nc(c(-c2c3nc(nc(n3nc2C)N[C@@H](CC)C)C)cc1)C)C
InChIKey: LBWQSAZEYIZZCE-SNVBAGLBSA-N
Synonyms: PEXACERFONT, 459856-18-9, BMS-562086, LF1VBG4ZUK, Dpc-a69448, DTXSID60196675, BMS562086, N-[(2R)-butan-2-yl]-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine, N-((2R)-BUTAN-2-YL)-8-(6-METHOXY-2-METHYLPYRIDIN-3-YL)-2,7-DIMETHYLPYRAZOLO(1,5-A)(1,3,5)TRIAZIN-4-AMINE, pexacerfontum, RefChem:928912, DTXCID00119166, N-((R)-sec-butyl)-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine, CRF1 ANTAGONIST, 8-(6-Methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo[1,5-a]-1,3,5-triazin-4-amine, 8-(6-Methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-((1R)-1-methylpropyl)pyrazolo(1,5-a)-1,3,5-triazin-4-amine, UNII-LF1VBG4ZUK, Pexacerfont [USAN], Pexacerfont [USAN:INN], 8-(6-Methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo[1,5-a]-1,3,5-triazin-4-amine, BMS 562086, PEXACERFONT [INN], Pexacerfont (USAN/INN), CHEMBL482950, orb1706825, SCHEMBL5235999, SCHEMBL29482255, BDBM29490, GTPL10379, CHEBI:177416, GLXC-15296, EX-A3079, ZB1563, AKOS040742389, CS-6630, DB12572, AC-32621, DA-66596, FP170137, HY-12127, MS-25202, NS00072040, D10022, D70085, Pyrazolo[1,5-a]-1,3,5-triazine, 13-15, Q7179563, 8-(6-methoxy-2-methyl-3-pyridyl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo[1,5-a][1,3,5]triazin-4-amine, Pyrazolo(1,5-a)-1,3,5-triazin-4-amine, 8-(6-methoxy-2-methyl-3-pyridinyl)-2,7-dimethyl-N-((1R)-1-methylpropyl)-
Theoretical properties:
molecular_formula: C18H24N6O
molecular_weight: 340.4 g/mol
exact_mass: 340.20115941 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 5
heavy_atom_count: 25
topological_polar_surface_area: 77.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Pexacerfont is a pyrazolopyridine.
chembl: PEXACERFONT is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Pexacerfont (INN, previously known as BMS-562,086) is a drug developed by Bristol-Myers Squibb which acts as a CRF1 antagonist.
Corticotropin-releasing factor (CRF), also known as corticotropin-releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. Chronic release of CRF and ACTH is believed to be directly or indirectly involved in many of the harmful physiological effects of chronic stress, such as excessive glucocorticoid release, diabetes mellitus, osteoporosis, stomach ulcers, anxiety, depression, and development of high blood pressure and consequent cardiovascular problems.
Pexacerfont is a recently developed CRF-1 antagonist which was in clinical trials for the treatment of anxiety disorders, and has also been proposed to be useful for the treatment of depression and irritable bowel syndrome.
A recent multicenter, randomized, double-blind, placebo-controlled trial found that pexacerfont (100 mg/day) did not separate from placebo on the primary outcome measure (the mean change from baseline to end point in the Hamilton Anxiety Scale score). These results suggest that blockade of CRF1 receptor may not be a feasible treatment for anxiety disorders in certain human populations.